Arquivos do dia: Julho 23, 2021
OMS | Desigualdade vacinal prejudica a recuperação econômica global.
23 Jul, 2021 | 10:19hComunicado de imprensa: Vaccine inequity undermining global economic recovery – World Health Organization
Painel: Global Dashboard for Vaccine Equity
Comentários: Urgent need for COVID-19 vaccine equity – University of Oxford E COVID-19 Vaccine Inequity Undermines Global Economic Recovery – Health Policy Watch
Comentário no Twitter (fio – clique para saber mais)
COVID-19 vaccine inequity is undermining 🌍 economic recovery. 🆕WHO, @UNDP and @BlavatnikSchool Dashboard on #VaccinEquity finds that low-income countries would add $38B to their GDP forecast if they had the same vaccination rate as high-income countrieshttps://t.co/BsYF2eYL1G
— World Health Organization (WHO) (@WHO) July 22, 2021
Opinião | Tocilizumabe no tratamento da COVID-19: quem se beneficia e como? – Os pesquisadores sugerem que inibidores de IL-6 talvez devam ser ministrados somente a pacientes com altos níveis de IL-6.
23 Jul, 2021 | 10:18hTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Relacionado: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. E M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. E RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes E Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. E M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Perspectiva | “Challenge Trials” com o SARS-CoV-2 (quando pessoas saudáveis são expostas deliberadamente ao virus, para fins de pesquisa) – Estabelecendo um modelo durante uma pandemia em evolução.
23 Jul, 2021 | 10:17hRelacionado: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (vários textos sobre o tema) E Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.
Colangite esclerosante secundária: uma nova complicação em pacientes críticos com COVID-19.
23 Jul, 2021 | 10:16hComo a variante Delta atinge sua disseminação ultrarrápida – “A carga viral é cerca de 1.000 vezes maior em pessoas infectadas com a variante Delta do que nos infectados com a cepa original do coronavírus, de acordo com estudo feito na China.”
23 Jul, 2021 | 10:15hHow the Delta variant achieves its ultrafast spread – Nature
O que são as variantes Delta, Gama, Beta e Alfa da Covid?
23 Jul, 2021 | 10:14hWhat are the Delta, Gamma, Beta and Alpha Covid variants? – BBC
Relacionado: Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”. E WHO renames COVID-19 variants with the Greek alphabet (i.e., Alpha, Beta, Gamma, etc), making them simple, easy to say and remember. The naming system aims to prevent calling COVID-19 variants by the places where they are detected, which is stigmatizing & discriminatory.
A variante Lambda: ela é mais infecciosa e escapa das vacinas? Virologista explica.
23 Jul, 2021 | 10:14hRelacionado: Lambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
CDC lança novas diretrizes para o tratamento de infecções sexualmente transmissíveis.
23 Jul, 2021 | 10:13hTabela de conteúdo: Sexually Transmitted Infections Treatment Guidelines, 2021
Relacionado (recém-lançado): WHO Guidelines for the management of symptomatic sexually transmitted infections.
Comentário no Twitter (fio – clique para saber mais)
Here's my greatest hits from today’s new @CDCSTD #STI Treatment Guidelines: a 🧵
1)#STI guidelines instead of #STD!
2)Expedited Partner Therapy: not just for “heterosexuals” 👏
3)#HepatitisC: screen all pregnant people
4)Rectal/throat GC/CT: consider for non-MSM like teens 👏 pic.twitter.com/gfEhrWpMKA— Ina Park (@InaParkMD) July 22, 2021
Nova série do The Lancet: Atividade Física 2021.
23 Jul, 2021 | 10:11hPágina principal: Physical Activity 2021 – The Lancet (necessário cadastro gratuito para todos os artigos)
Resumo e comentário: Experts call for immediate action to ensure physical activity is built into everyday lives – News Medical
Comentário no Twitter (fio – clique para saber mais)
🆕 In the early stages of the #pandemic, #PhysicalActivity was considered *essential* for health by many governments—but inactivity remains a major issue.
Ahead of #Tokyo2020, we launch @TheLancet #PhysicalActivity21 Series 🤸♀️👨🦽
Access here: https://t.co/j0GhLGKAAD pic.twitter.com/mrcOnRPyR6
— The Lancet (@TheLancet) July 22, 2021
Posicionamento de sociedades de cardiologia sobre a biópsia endomiocárdica.
23 Jul, 2021 | 10:08h
Comentário no Twitter
🚨A must read – out now in JCF: Position Statement on Endomyocardial Biopsy 🫀 – @HFSA @escardio @ESCardioNews #CardioTwitter #FunctionNotFailure #HeartSuccess @rcstarling @MRMehraMD @BiykemB @Filippatos @robmentz @dranulala https://t.co/33FPZDBviN pic.twitter.com/VJEzGLIRIg
— Journal of Cardiac Failure (@JCardFail) July 21, 2021